CRISPR patent for Merck’s MilliporeSigma

Merck’s MilliporeSigma said the European Patent Office (EPO) issued a “Notice of Intention to Grant” for MilliporeSigma’s patent application covering the company’s CRISPR technology used in a genomic integration method for eukaryotic cells.

A related patent was approved in Australia in June 2017.

“This is a significant and exciting decision by the EPO, and we view this announcement as recognition of MilliporeSigma’s important contributions to the genome-editing field,” said Udit Batra, CEO, MilliporeSigma.

“This patent provides protection for our CRISPR technology, which will give scientists the ability to advance treatment options for the toughest medical challenges we face today.”